| Next 10 |
Ad
TCRT News and Press Alaunos Therapeutics Inc.
News | Alaunos Therapeutics Inc. (NASDAQ:TCRT)
-
2023-05-26 15:36:17 ET Alaunos Therapeutics ( NASDAQ: TCRT ) fell ~17% on Friday as investors reacted to data from a Phase 1/2 trial for its T-cell receptor (TCR) cell therapy candidate in patients with solid tumors harboring KRAS or TP53 genetic mutations. As of Feb. 2023, ...
-
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in perip...
-
2023-05-10 15:40:23 ET Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Conference Call May 10, 2023 09:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle - Chief Executive Officer Drew Deniger - Vice President of Research & Deve...
-
2023-05-10 07:09:24 ET Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q1 GAAP EPS of -$0.04 in-line. As of March 31, 2023, Alaunos had approximately $37.4 million in cash balances, which included restricted cash of approximately $13.9 million. Based on current op...
-
Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended exclusive licensing agreement wit...
-
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will rep...
-
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster prese...
-
HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointmen...
-
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company m...
-
2023-03-07 10:35:21 ET Alaunos Therapeutics, Inc. (TCRT) Q4 2022 Earnings Conference Call March 7, 2023 08:30 AM ET Company Participants Danielle Dudgeon - Stern IR Kevin Boyle Senior - CEO Drew Deniger - VP, Research and Development Abhi Srivastava - VP, Tec...
Stock Information
Trending Stock
8.33%Change Percent:
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Get TCRT Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
